+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Vitiligo Market, Patients by Countries, Drugs, Companies, Clinical Study, Growth Drivers, and Challenges

  • ID: 4715442
  • Report
  • December 2018
  • Region: Global
  • 100 Pages
  • Renub Research
1 of 4
The Global Vitiligo Market will be US$ 2.4 Billion by the Year 2024

FEATURED COMPANIES

  • AXIM Biotechnologies
  • Boston Pharmaceutical
  • Bristol-Myers Squibb
  • Castle Creek Pharma
  • Clinuvel Pharmaceuticals
  • Dermavant Sciences
  • MORE

Vitiligo is a long-term skin disease in which patches of the skin lose their color. The skin patches affected by the disease Vitiligo become white. This happens because melanocytes within the skin die off. The skin pigmentation, melanin, due to which skin has its color, protection from solar UV rays this all happens because of melanocytes cells. Growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing diseases awareness and expected approval of Vitiligo drugs are some of the driving force for the growth of this market. However, the shortage of dermatologists and available treatments having a longer duration of times are major challenges for the growth of this market. According to this research, global Vitiligo market will be US$ 2.4 Billion by the year 2024.

Vitiligo disease prevalence varies between race, regions, and countries. It is expected that overall prevalence falls between 1-2 percent of the total population. Although Vitiligo disease can arise at any age, it mostly occurs to young and middle age people. At present globally over 21 Million people has suffered from this diseases. There is a number of drugs manufacture working for Vitiligo drugs development across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc. and their Vitiligo drugs development are in various stages.

This report titled “Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges” provides a complete analysis of global vitiligo drugs market.

India and China are Key Contributors in the Global Vitiligo Patient Population

Vitiligo patient’s population is growing across all parts of the world. Patient’s growth rates vary in the countries covered in the report United States, United Kingdom, France, Germany, Italy, India, China, and Japan. India and China are key contributors to the global vitiligo patient population.

Vitiligo Pipe Line Drugs are Key Strength for this Market Place

In the global vitiligo market, vitiligo pipeline drugs will play a major role in the growth of this market. At present several drugs such as ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001 etc. are in preclinical, IND, Phase I, Phase II and Phase III stage.
Key Drugs Development Companies are working in this Market Place

Key drugs development companies are working in this marketplace across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc.

Segments - Global Vitiligo Market

  • Vitiligo Patients Population
  • Vitiligo Market

Countries - Global Vitiligo Market

  • United States
  • United Kingdom
  • France
  • Germany
  • Italy
  • India
  • China
  • Japan

Global Vitiligo Market - Drugs Profile Covered

  • ARN-4079
  • ATI-502
  • AX-1602
  • BOS-47
  • CCP-070
  • Cerdulatinib (RVT-502)
  • HuABC-2
  • Abatacept
  • Topical Ruxolitinib
  • VLRX-001

Companies Covered

  • AXIM Biotechnologies
  • Incyte Corporation
  • Bristol-Myers Squibb
  • Clinuvel Pharmaceuticals

Each Company Covered in this Report has Following Details

  • Company Overview
  • Company Initiatives
  • Financial Insight
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AXIM Biotechnologies
  • Boston Pharmaceutical
  • Bristol-Myers Squibb
  • Castle Creek Pharma
  • Clinuvel Pharmaceuticals
  • Dermavant Sciences
  • MORE

1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Global Vitiligo Patient Numbers & Market
4.1 Vitiligo Patients Numbers
4.2 Vitiligo Market

5. Share - Global Vitiligo Patient Numbers & Market
5.1 Vitiligo Patient Numbers Share
5.2 Vitiligo Market Share

6. United States
6.1 Vitiligo Patient Numbers
6.2 Vitiligo Market

7. United Kingdom
7.1 Vitiligo Patient Numbers
7.2 Vitiligo Market

8. France
8.1 Vitiligo Patient Numbers
8.2 Vitiligo Market

9. Germany
9.1 Vitiligo Patient Numbers
9.2 Vitiligo Market

10. Italy
10.1 Vitiligo Patient Numbers
10.2 Vitiligo Market

11. India
11.1 Vitiligo Patient Numbers
11.2 Vitiligo Market

12. China
12.1 Vitiligo Patient Numbers
12.2 Vitiligo Market

13. Japan
13.1 Vitiligo Patient Numbers
13.2 Vitiligo Market

14. Vitiligo Pipe Line Drugs
14.1 ARN-4079
14.2 ATI-502
14.3 AX-1602
14.4 BOS-475
14.5 CCP-070
14.6 Cerdulatinib (RVT-502)
14.7 HuABC-2
14.8 Abatacept
14.9 Topical Ruxolitinib
14.10 VLRX-001

15. Clinical Study of Vitiligo Market

16. Growth Drivers
16.1 Growing Importance of Aesthetic Appeal
16.2 World Vitiligo Day: Increases Vitiligo Awareness

17. Global Vitiligo Market - Challenges
17.1 Shortage of Dermatologists
17.2 Available Treatments are Not Much Effective

18. AXIM Biotechnologies, Inc.
18.1 Company Overview
18.2 Initiatives
18.2.1 Point 1
18.2.2 Point 2
18.2.3 Point 3
18.3 Financial Insight

19. Incyte Corporation
19.1 Company Overview
19.2 Initiatives
19.2.1 Point 1
19.2.2 Point 2
19.3 Financial Insight

20. Bristol-Myers Squibb
20.1 Company Overview
20.2 Initiatives
20.2.1 Point 1
20.2.2 Point 2
20.3 Financial Insight

21. Clinuvel Pharmaceuticals Ltd
21.1 Company Overview
21.2 Company Initiatives
21.2.1 Point 1
21.2.2 Point 2
21.3 Financial Insight

List of Figures:
Figure 4 1: Global - Vitiligo Patients Population (Thousand), 2012 - 2017
Figure 4 2: Global - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024
Figure 4 3: Global - Vitiligo Market (Million US$), 2012 - 2017
Figure 4 4: Global - Forecast for Vitiligo Market (Million US$), 2018 - 2024
Figure 5 1: Global - Vitiligo Patients Population Share (Percent), 2012 - 2017
Figure 5 2: Global - Forecast for Vitiligo Patients Population Share (Percent), 2018 - 2024
Figure 5 3: Global - Vitiligo Market Share (Percent), 2012 - 2017
Figure 5 4: Global - Forecast for Vitiligo Market Share (Percent), 2018 - 2024
Figure 6 1: United States - Vitiligo Patients Population (Thousand), 2012 - 2017
Figure 6 2: United States - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024
Figure 6 3: United States - Vitiligo Market (Million US$), 2012 - 2017
Figure 6 4: United States - Forecast for Vitiligo Market (Million US$), 2018 - 2024
Figure 7 1: United Kingdom - Vitiligo Patients Population (Thousand), 2012 - 2017
Figure 7 2: United Kingdom - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024
Figure 7 3: United Kingdom - Vitiligo Market (Million US$), 2012 - 2017
Figure 7 4: United Kingdom - Forecast for Vitiligo Market (Million US$), 2018 - 2024
Figure 8 1: France - Vitiligo Patients Population (Thousand), 2012 - 2017
Figure 8 2: France - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024
Figure 8 3: France - Vitiligo Market (Million US$), 2012 - 2017
Figure 8 4: France - Forecast for Vitiligo Market (Million US$), 2018 - 2024
Figure 9 1: Germany - Vitiligo Patients Population (Thousand), 2012 - 2017
Figure 9 2: Germany - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024
Figure 9 3: Germany - Vitiligo Market (Million US$), 2012 - 2017
Figure 9 4: Germany - Forecast for Vitiligo Market (Million US$), 2018 - 2024
Figure 10 1: Italy - Vitiligo Patients Population (Thousand), 2012 - 2017
Figure 10 2: Italy - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024
Figure 10 3: Italy - Vitiligo Market (Million US$), 2012 - 2017
Figure 10 4: Italy - Forecast for Vitiligo Market (Million US$), 2018 - 2024
Figure 11 1: India - Vitiligo Patients Population (Thousand), 2012 - 2017
Figure 11 2: India - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024
Figure 11 3: India - Vitiligo Market (Million US$), 2012 - 2017
Figure 11 4: India - Forecast for Vitiligo Market (Million US$), 2018 - 2024
Figure 12 1: China - Vitiligo Patients Population (Thousand), 2012 - 2017
Figure 12 2: China - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024
Figure 12 3: China - Vitiligo Market (Million US$), 2012 - 2017
Figure 12 4: China - Forecast for Vitiligo Market (Million US$), 2018 - 2024
Figure 13 1: Japan - Vitiligo Patients Population (Thousand), 2012 - 2017
Figure 13 2: Japan - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024
Figure 13 3: Japan - Vitiligo Market (Million US$), 2012 - 2017
Figure 13 4: Japan - Forecast for Vitiligo Market (Million US$), 2018 - 2024
Figure 14 1: Vitiligo Pipe Line Drug - ARN-4079 Status (2018)
Figure 14 2: Vitiligo Pipe Line Drug - ATI-502 Status (2018)
Figure 14 3: Vitiligo Pipe Line Drug - AX-1602 Status (2018)
Figure 14 4: Vitiligo Pipe Line Drug - BOS-475 Status (2018)
Figure 14 5: Vitiligo Pipe Line Drug - CCP-070 Status (2018)
Figure 14 6: Vitiligo Pipe Line Drug - Cerdulatinib (RVT-502) Status (2018)
Figure 14 7: Vitiligo Pipe Line Drug - HuABC-2 Status (2018)
Figure 14 8: Vitiligo Pipe Line Drug - Abatacept Status (2018)
Figure 14 9: Vitiligo Pipe Line Drug - Topical Ruxolitinib Status (2018)
Figure 14 10: Vitiligo Pipe Line Drug - VLRX-001 Status (2018)
Figure 18 1: Axim Biotechnologies, Inc - Global Sales (US$), 2015 - 2017
Figure 18 2: Axim Biotechnologies, Inc - Forecast for Global Sales (US$), 2018 - 2024
Figure 19 1: Incyte Corporation - Global Sales (Million US$), 2012 - 2017
Figure 19 2: Incyte Corporation - Forecast for Global Sales (Million US$), 2018 - 2024
Figure 20 1: Bristol-Myers Squibb - Global Sales (Million US$), 2012 - 2017
Figure 20 2: Bristol-Myers Squibb - Forecast for Global Sales (Million US$), 2018 - 2024
Figure 21 1: Clinuvel Pharmaceuticals Limited - Global Sales (Thousand US$), 2013 - 2017
Figure 21 2: Clinuvel Pharmaceuticals Limited - Forecast for Global Sales (Thousand US$), 2018 - 2024

List of Tables:
Table 15-1: Global - Vitiligo Market Clinical Study, 2018

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AXIM Biotechnologies
  • Boston Pharmaceutical
  • Bristol-Myers Squibb
  • Castle Creek Pharma
  • Clinuvel Pharmaceuticals
  • Dermavant Sciences
  • Incyte Corporation
  • JN Biosciences
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll